Showing results (131-140 of 152) with videos related to
Sort By:
Pageof 16
Breast Cancer Research and Treatment|December 28, 2017
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)Noam Ponde, Ian Bradbury, Matteo Lambertini, et al.International Journal of Molecular Sciences|February 23, 2020
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant TherapySerena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast CancerIoannis A Vathiotis, Myrto K Moutafi, Prajan Divakar, et al.The Oncologist|October 14, 2022
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL TrialSerena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, et al.European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2024
Clinicopathological and molecular predictors of [<sup>18</sup>F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trialAntonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, et al.Nature Communications|November 4, 2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trialsMattia Rediti, Aranzazu Fernandez-Martinez, David Venet, et al.Journal for Immunotherapy of Cancer|June 21, 2022
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complexDieke J van Rees, Panagiota Bouti, Bart Klein, et al.European Journal of Cancer (Oxford, England : 1990)|August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancerJens Huober, Eileen Holmes, José Baselga, et al.European Journal of Cancer (Oxford, England : 1990)|January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancerPaolo Nuciforo, John Townend, Martine J Piccart, et al.Lancet (London, England)|January 20, 2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialJosé Baselga, Ian Bradbury, Holger Eidtmann, et al.Pageof 16